cyrilzakka/clinical-trials huggingface dataset:
The Effect of Different Types of Mouthwash on Extraction Sockets' Healing

The goal of this clinical trial is to assess the effect of four different types of mouthwash on socket healing after surgical extractions in male or female patients aged 18 years and older who have a unilateral impacted mandibular third molar indicated for extraction. The main questions it aims to answer are:

The effect of Bone Bioactive Liquid (BBL) mouthwash, Hyaluronic Acid (HA) mouthwash, the Chlorhexidine digluconate (CHX) mouthwash and Warm Saline Mouth Rinse (WSMR) on socket healing after surgical extractions.

The effect of BBL mouthwash, HA mouthwash, the CHX mouthwash and WSMR on patient related factors and their quality of life.

Recruited Participants will be randomized into four intervention groups:

1. First group will receive BBL mouthwash.
2. The second group will receive CHX mouthwash.
3. The third group will be prescribed HA mouthwash.
4. The fourth group will receive Warm Saline Mouth Rinse.


Eligibility Criteria:
Inclusion Criteria:

* Male or female patients aged 18 years and older who have a unilateral impacted mandibular third molar that is indicated for extraction with bone removal and the presence of an adjacent second molar.

Exclusion Criteria:

* Soft tissue impaction that will not need any bone removal.
* Presence of any acute oral infection including active Pericoronitis.
* Patients who have undergone radiotherapy in the head and neck region, chemotherapy or systemic long-term corticosteroid treatment.
* Patients receiving medications known to induce gingival hyperplasia; anticonvulsant (phenytoin), immunosuppressant (cyclosporine A), and various calcium channel blockers (nifedipine, verapamil, diltiazem).
* Patients who have taken systemic antibiotics less than 3 months prior to baseline.
* Presence of uncontrolled diabetes, severe nutritional deficiencies and endocrine disturbances.
* Presence of immune deficiency or any immune disease.
* Intravenous bisphosphonates or Oral bisphosphonate intake for more than 3 years.
* Smokers and alcoholics.
* Pregnant or lactating females.
* Hypersensitivity to one of the ingredients listed in any of the mouthwashes, especially chlorhexidine as reactions to this has been reported in the literature.
Turkish Version of Breast Edema Questionnare: Validity and Reliability Study

This study was planned to investigate the complaint of breast edema after breast conserving surgery and radiotherapy, which are considered as the main treatment modalities for breast cancer. The incidence of breast edema after these treatments ranges from 0% to 90.4%. In contrast to arm lymphedema, which has been described in detail in the literature, only a few studies have investigated breast edema. There is no survey study that comprehensively examines the presence of lymphedema and its clinical features (duration, severity, location). Studies to assess breast edema after breast cancer treatment have revealed the need for a condition-specific scale. Therefore, the "Breast Edema Questionnaire" was developed to assess breast edema in women who have undergone breast cancer surgery. The original language of this questionnaire is German and its reliability and validity has not been studied in another language. In this study, the validity and reliability of this questionnaire, which specifically assesses breast edema, will be tested in Turkish women.


Eligibility Criteria:
Inclusion Criteria:

* Individuals with a diagnosis of breast cancer who have undergone breast-conserving surgery
* individuals who have signed the Informed Consent form

Exclusion Criteria:

* illiterate individuals
Mechanisms of Macrophage Polarization in HIRI in Patients With NAFLD

To better understand the occurrence of hepatic ischemia-reperfusion injury (IRI) in patients with non-alcoholic fatty liver disease (NAFLD) and the role of macrophage polarization in this process, this study will retrospectively collect clinical data from patients who underwent partial hepatectomy at Beijing Tsinghua Changgung Hospital between September 2021 and March 2025. Additionally, clinical information and liver blood samples from patients scheduled for partial hepatectomy from April 2025 onward will be prospectively collected. These samples will include normal liver tissue from the resected portion, as well as 5 mL of venous blood obtained before and after surgery. The investigators will compare the severity of hepatic IRI, the expression of macrophage polarization-related proteins, and macrophage polarization markers in blood samples between NAFLD patients and controls. The study aims to determine whether NAFLD patients experience more severe hepatic IRI and to elucidate the role and mechanisms of macrophage polarization in this context. The findings will provide a theoretical basis for understanding the molecular mechanisms underlying hepatic IRI in NAFLD patients, thereby identifying potential therapeutic targets to prevent IRI and improve prognosis in NAFLD patients undergoing partial hepatectomy.


Eligibility Criteria:
Inclusion Criteria:

* The vital organ systems (heart, lungs and kidneys) have sufficient functional reserves.

Exclusion Criteria:

* No hepatic inflow occlusion (Pringle maneuver) was applied during surgery.
* American Society of Anesthesiologists (ASA) Physical Status Classification \> Grade III.
* Secondary causes of hepatic steatosis were excluded, including viral hepatitis, drug-induced liver injury, total parenteral nutrition, Wilson's disease, and autoimmune liver diseases.
* Prior chemotherapy or radiotherapy before the planned surgery.
* Use of anticoagulant medications.
Shorter Scalp Cooling Time in Paclitaxel

Chemotherapy-induced alopecia (CIA) is one of the most distressing side effects for patients. Scalp cooling can prevent or minimise CIA in approximately half of all patients, depending on many factors, e.g. type and dosage of chemotherapy. High rates of success are seen in patients treated with taxanes, up to 80-90%. Previous research has shown comparable results of scalp cooling in docetaxel-treated patients when shortening the post-infusion cooling time (PICT) from the initial standard of 90 minutes to 45- and 20 minutes. A shorter PICT is an advantage for both the patient, who can spend less time in the hospital, as well for the logistics at oncological departments. Paclitaxel and docetaxel are both classical taxanes, that share similar mechanisms of action and have comparable plasma terminal half-life times, therefore it seems plausible that the PICT can be shortened for paclitaxel-treated patients as well.


Eligibility Criteria:
Inclusion Criteria:

* Patients receiving weekly-administered paclitaxel-containing chemotherapy (minimal 3 planned administrations) in a dose of 80-90 mg/m2 Paclitaxel monotherapy, Paclitaxel in combination with carboplatin, Paclitaxel in combination with monoclonal antibodies: Bevacizumab or Trastuzumab
* Age ≥ 18 years
* WHO performance status 0-2
* Survival expectation must be \> 3 months
* Written informed consent according to the local Ethics Committee requirements

Exclusion Criteria:

* Treatment with paclitaxel in sequential schemes with other alopecia inducing agents such as paclitaxel monotherapy after adriamycin, cyclophosphamide (AC) or paclitaxel monotherapy after 5-fluouracil, epirubicin, cyclophosphamide (FEC) treatment
* Alopecia before the start of the study
* Rare cold-related disorders: Cold sensitivity, Cold agglutinin disease, Cryoglobulinaemia, Cryofibrinogenaemia, Cold posttraumatic dystrophy
Behavioral Processes Underlying Reward Processing in Depression

The purpose of this project is to use behavioral techniques to investigate emotional processing in subjects with major depression and healthy comparison subjects.

A promising strategy for parsing the heterogeneity of Major Depressive Disorder is to identify phenotypes characterized by reliable functional abnormalities. Anhedonia, the lack of reactivity to pleasurable stimuli, is considered a trait marker for depression. Using an objective behavioral task this project aims to investigate hedonic capacity in subjects meeting a DSM-IV diagnosis of Major Depressive Disorder.

Eligibility Criteria:
Inclusion Criteria:

Depressed participants:

* Right-handed
* DSM-IV diagnosis of MDD
* Score of at least 17 on the 21-item HAM-D scale
* Absence of any psychotropic medications for at least 2 weeks (6 months for dopaminergic drugs (including methylphenidate), 6 weeks for fluoxetine, and 4 weeks for neuroleptics and benzodiazepines because of longer half-lives.)
* No current or past history of MDD with psychotic features
* Absence of any other Axis I or Axis II diagnosis (Including bipolar disorder and current or lifetime history of alcohol or substance abuse or dependence.) Particularly, subjects with a history of alcoholism and substance abuse will be excluded, since dopaminergic alterations have been reported in these conditions. Exclusion of patients with comorbid Axis I or Axis II diagnoses will be necessary as evidence exists of alteration in dopamine receptor density in detached personality and social phobia. The alteration of dopamine in the brain may in turn alter behavior.
* Absence of significant medical conditions
* Absence of ECT in the previous 6 months
* Ability to provide informed consent/authorization

Bipolar participants:

* Both genders and all ethnic origins
* Age between 18 and 64
* Right-handed
* DSM-IV diagnosis of Bipolar Disorder I or II
* Score of at least 17 on the 21-item Hamilton Depression Rating Scale (HAM-D)
* Absence of any psychotropic medications for at least 2 weeks (6 months for dopaminergic drugs (including methylphenidate), 6 weeks for fluoxetine, and 4 weeks for neuroleptics and benzodiazepines because of longer half-lives.)
* No current or past history of MDD with psychotic features
* Absence of any other Axis I or Axis II diagnosis (Including current or lifetime history of alcohol or substance abuse or dependence.) Particularly, subjects with a history of alcoholism and substance abuse will be excluded.
* Absence of significant medical conditions
* Absence of ECT in the previous 6 months
* Ability to provide informed consent/authorization

Control Participants:

* Right-handed
* Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse), as assessed by the SCID
* Absence of any medications for at least 2 weeks
* Informed consent/authorization

Exclusion Criteria:

* Left-handed/ambidextrous
* Evidence of neurological illness
* Current alcohol or substance abuse
* Serious suicide or homicide risk
Associations Between Diabetes Care and Haptoglobin Genotype On outComes

The ADHOC Cohort comprised 3044 DM individuals, treated in 47 CHS primary care clinics, that underwent haptoglobin genotyping between 2 march, 2005 and 26 September 2006. Individuals were eligible for inclusion if they had DM and were 55 years of age or older. All treatment decisions, regarding all aspects of care and follow-up of the study participants, remained at the discretion of the individual's primary care physician, who was blinded to the individual's Hp type. Hp distribution was: Hp 1-1 285 (9.4%); Hp 2-1 1248 (41.0%); Hp 2-2 1511 (49.6%).

Hypothesis: strict glucose control (HbA1c\<7%) reduces the rate of cardiovascular events only to diabetic patients with the Hp 2-2 phenotype. We also postulated that, since Hp 2-2 DM individuals are at an increased genetic susceptibility for cardiovascular disease (CVD), this unique cohort merits an investigation on the associations between various CVD risk variables and CVD events and establish whether any evident association was dependent of the individual's Hp type.


Eligibility Criteria:
Inclusion Criteria:

* Diabetic patients
* 55 years old or older at the time of ICARE initiation.
* Known haptoglobin genotype
* Signed informed consent for ICARE study and registry
Non-invasive Flow Measurements in Patients with Lower Extremity Arterial Disease (LEAD)

This concerns a study with patients who will undergo endovascular treatment. Blood flow will be measured by 2D Duplex Ultrasound. Contrast data will be collected that will be processed offline.


Eligibility Criteria:
Inclusion Criteria:

* Patients referred to the vascular surgery outpatient clinic (LUMC) with PAD
* Age ≥18 years
* Superficial femoral artery (SFA) stenosis (\>70% occluded)
* Elective for a percutaneous transluminal angioplasty procedure
* Written informed consent

Exclusion Criteria:

* Contraindications to angiography, such as severe renal insufficiency (eGFR\< 20)
* Non-correctable bleeding disorder.
Geranium Oil and Its Components for the Relief of Numbness-OB 100

This study is designed to evaluate the effectiveness of geranium oil and its components in the relief of numbness and the restoration of sensations.

This is a pilot study to define the time course, the incidence of sensation restoration and the improvement in nerve conduction in people with numbness by using topical geranium oil.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Neuropathy with the inability to feel touch in a standard nylon filament test
* Signed informed consent

Exclusion Criteria:

* Pregnant or nursing
* Known allergies to geranium oil or geranium oil fractions
* Open sore in the area of numbness
* Migraine headaches or headaches to strong smells
Effect of Hyaluronic Acid on Perimplantitis

The effect of the hyaluronic acid treatment on peri-implantitis has not been tested. The aim was to analyze the effect of a hyaluronic acid-containing gel on the clinical variables and the expression of biochemical inflammatory markers in the crevicular fluid of implants receiving perimplantitis treatment.

The aim was to analyze the effect of a hyaluronic acid-containing gel on the clinical variables and the expression of biochemical inflammatory markers in the crevicular fluid of implants receiving perimplantitis treatment.

A randomized, controlled, double-blind clinical trial was designed on 100 perimplantitis affected implants placed in 61 subjects. Inclusion criteria were implants with at least 1 year of functional loading and with diagnosis of perimplantitis following the criteria from the Association of Dental Implantology. All implant received perimplantitis treatment. Each patient was randomly assigned to receive a gel containing 0.8% HA (Test group), a gel without HA (Placebo group) or no gel treatment (Control group). After a first gel application at baseline, test and placebo patients performed gel applications at home 3 times/day for 45 days. Clinical variables of each implant were recorded at baseline, 45 and 90 days (probing depth, attachment loss, bleeding). Intraoral radiographs of each implants were performed to measure marginal bone level. Peri-implant crevicular fluid was collected from each implant at baseline and after 45 days of treatment, to assess IL-1β and TNFα levels by ELISA technique. Clustering analysis, considering multiple implants within each patient, was performed.

Eligibility Criteria:
Inclusion Criteria:

* Implants with at least one year of functional load.
* Implants diagnosed with peri-implantitis according to the criteria of the Association of Dental Implantology.

Exclusion Criteria:

* Previous peri-implantitis treatment.
* Pregnancy or breast-feeding.
* Neoplastic disease.
* Antibiotic treatment during the previous month.
Cancer as a complicATion in reCipients of Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Disease iNdiCation trEated in FRance and Canada?

Autologous Hematopoietic Stem Cell Transplantation (AHSCT) is a treatment option for several types of Autoimmune Disease (AD) in patients who remain active despite disease modifying therapies. In this setting, AHSCT was shown to improve overall survival, event free survival and quality of life, with a grade A level evidence for systemic sclerosis (SSc) and multiple sclerosis (MS) patients and its benefit varies according to the AD type and the patient status for the other indications. The number of AHSCT for AD has increased in the past twenty years at each country level in Europe and also in Canada.

Information about cancer after AHSCT for AD is scant, although the AD patients population per se has an increased rate of cancer. This cancer risk can be explained in part by the long term use of immunosuppressive drugs or by other risk factors related to the AD (as in SSc or Crohn) or to the patient. In addition to pretransplant potential risk factors for cancer in AD patients, the use of conditioning regimen, which may vary from low, medium or high immunosuppressive to myeloablative chemotherapy when irradiation is added to the proecedure, may favor the onset of cancer after AHCST. Updated analysis and review of the literature until march 2023 led us to identify only twenty-two cases of cancer or hematological malignancies reported after AHSCT recipients for an AD.

The incidence of cancer after AHSCT for AD was never considered as a primary endpoint in any previous study.

In this context, the aim of this study is to describe the incidence of cancer after autologous hematopoietic stem cell transplantation (AHSCT) for auto-immune diseases (AD) in the French MATHEC (French scientific network for AD and cellular therapies) and the Ottawa and Calgary patients cohorts from Day 0 until twenty years follow up after AHSCT.


Eligibility Criteria:
Inclusion Criteria:

1. Aged ≥ 18 years at AHSCT
2. Underwent first AHSCT for any AD indication
3. Included in the French MATHEC-SFGM-TC registry or the Canadian Ottawa and Calgary databases
4. AHSCT between January, 1st, 2000 and December, 31st, 2022
5. Informed consent for data registration in the respective original registry/database

Exclusion Criteria:

None
A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)

This is an open-label, dose escalation gene transfer therapy study evaluating the safety of SRP-9004 (patidistrogene bexoparvovec) via isolated limb infusion (ILI) administration in approximately 6 participants with LGMD2D.


Eligibility Criteria:
Key Inclusion Criteria:

* Cohort 1A must be adult and wheelchair-dependent; Cohorts 1B and 2 will be participants of age 7 or older.
* Confirmed alpha-sarcoglycan deficiency or identified sarcoglycan alpha (SGCA) deoxyribonucleic acid (DNA) mutation.
* Participants enrolled in Cohorts 1B or 2 must be able to walk independently, but must exhibit signs of lower extremity weakness (that is, a Gowers' sign, use a handrail for climbing stairs) and walk ≤80% of predicted distance on the 6 minute walk test (6MWT) based on normative data.

Key Exclusion Criteria:

* Active viral infection based on clinical observations.
* The presence of SGCA mutations without weakness or loss of function.
* Symptoms or signs of cardiomyopathy.
* Serological evidence of human immunodeficiency virus (HIV), Hepatitis B, or C infection.
* Diagnosis of (or ongoing treatment for) an autoimmune disease.
* Participants with AAVrh74 or AAV8 binding antibody titers ≥ 1:50 as determined by enzyme-linked immunosorbent assay (ELISA) immunoassay.

Other inclusion/exclusion criteria apply.
Efficacy of Probiotic Lactobacillus Crispatus M247 in Promoting High-risk Human Papillomavirus (HR-HPV) Infection Clearance and Modifying Vaginal Microbiota

This clinical trial evaluates the efficacy of the probiotic strain Lactobacillus crispatus M247 in promoting the clearance of genital high-risk human papillomavirus (HR-HPV) infection and restoring the balance of the vaginal microbiota. The study adopts a multicenter, randomized, single-blind, longitudinal, prospective design involving HR-HPV-positive patients. Primary outcomes include HR-HPV clearance rates and microbiota composition changes.

This study investigates the potential benefits of Lactobacillus crispatus M247, a probiotic strain with proven ability to promote vaginal health, in the management of HR-HPV infections. Lactobacillus crispatus M247 has demonstrated superior probiotic properties, including the ability to produce lactic acid and hydrogen peroxide, which contribute to maintaining a stable vaginal microbiota and potentially inhibiting HR-HPV persistence.

Participants will be randomized to receive either Lactobacillus crispatus M247 or a placebo over a specified study period. The primary aim is to evaluate the probiotic's efficacy in enhancing HR-HPV clearance rates and restoring a balanced vaginal microbiota. Secondary objectives include assessing changes in cervical cytology and participant-reported outcomes on vaginal health. By focusing exclusively on the role of Lactobacillus crispatus M247, the study seeks to establish its clinical relevance in HR-HPV management and its potential as a therapeutic intervention.

Eligibility Criteria:
Inclusion Criteria:

* Women aged 18-69 years.
* First diagnosis of HR-HPV infection via DNA-HPV screening.
* Cytology results showing ASC-US or LSIL.
* Negative colposcopy or biopsy (absence of lesions).
* Ability to provide written informed consent.

Exclusion Criteria:

* Prior HPV vaccination.
* History of cervical treatments for pre-neoplastic pathology.
* Cytology showing HSIL (High-Grade Squamous Intraepithelial Lesion) requiring treatment.
* Current treatment with antibiotics, immunomodulatory, or immunosuppressive therapies.
* Diagnosed immune system or neoplastic diseases requiring chemotherapy.
* Pregnancy, lactation, or planning to become pregnant within 6 months.
* Known hypersensitivity to product components.
Identification of Integrin ab Expression in Lung Cancer Patients

It has been reported that the expression rates of integrin αvβ3 and integrin αvβ5 in NSCLC are 89% and 100%, respectively. Among RGD (Arg-Gly-Asp) peptides, cRGDyK peptide (cRGD) known as integrin ανβ3 and ανβ5 antagonist has been widely used for targeting various cancers including NSCLC, glioblastoma, and colon carcinoma as well as prostate cancer. In this study, the investigators aim to analysis the expression of integrin ανβ3 in lung cancer patients.

Patient samples: From the Human Resource Bank of the Institute of Pathology, Korea University, the investigators collected paraffin-embedded tissue sections from 61 patients with NSCLC (adenocarcinoma =50, squamous cell carcinoma = 11) who had undergone surgical treatment for NSCLC at Korea University Guro Hospital between 2015 and 2018 under the IRB of Guro Hospital 2019GR0460. Samples were excluded when patients had undergone perioperative chemo- or radiotherapy. Among the tissues excised from lung cancer patients, lung cancer and normal tissue were classified as pathologically, defined as normal tissue and cancer tissue, and stained with an integrin ανβ3 primary antibody.

Eligibility Criteria:
Inclusion Criteria:

* NSCLC (adenocarcinoma or squamous cell carcinoma) who had undergone surgical treatment for NSCLC at Korea University Guro Hospital between 2015 and 2018

Exclusion Criteria:

* patients had undergone perioperative chemo- or radiotherapy